Explore the Global PD1 Non-Small Cell Lung Cancer Treatment Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

PD1 Non-Small Cell Lung Cancer Treatment Market

Key Insight

PD1 non-small cell lung cancer treatment sales will grow through 2036, led by pembrolizumab at 62.0% of the drug type segment in 2026. The market was valued at USD 31.74 billion in 2025 and is expected to be worth USD 81.90 billion by 2036, creating an incremental opportunity of USD 47.30 billion.

April 28, 2026

Anurag Sharma

291 Pages

Cite this Report

PD1 Non-Small Cell Lung Cancer Treatment Market

https://www.futuremarketinsights.com/reports/pd1-non-small-cell-lung-cancer-treatment-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

BlackRock
BeiGene
Bristol-Myers Squibb
Eli Lilly and Company
GSK plc
Merck KGaA
Novartis
Regeneron Pharmaceuticals
Roche
L'Oréal

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

PD1 Non-Small Cell Lung Cancer Treatment Market

Key Players

Similar Industry Reports